[go: up one dir, main page]

BRPI0813003A2 - Promotor - Google Patents

Promotor

Info

Publication number
BRPI0813003A2
BRPI0813003A2 BRPI0813003-5A2A BRPI0813003A BRPI0813003A2 BR PI0813003 A2 BRPI0813003 A2 BR PI0813003A2 BR PI0813003 A BRPI0813003 A BR PI0813003A BR PI0813003 A2 BRPI0813003 A2 BR PI0813003A2
Authority
BR
Brazil
Prior art keywords
seq
promoter
district attorney
attorney
district
Prior art date
Application number
BRPI0813003-5A2A
Other languages
English (en)
Inventor
Christian Klein
Erhard Kopetzki
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38476213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0813003(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0813003A2 publication Critical patent/BRPI0813003A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Finger-Pressure Massage (AREA)
  • Percussion Or Vibration Massage (AREA)
BRPI0813003-5A2A 2007-06-29 2008-06-25 Promotor BRPI0813003A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07012772 2007-06-29
PCT/EP2008/005135 WO2009003622A1 (en) 2007-06-29 2008-06-25 Promoter

Publications (1)

Publication Number Publication Date
BRPI0813003A2 true BRPI0813003A2 (pt) 2014-10-14

Family

ID=38476213

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813003-5A2A BRPI0813003A2 (pt) 2007-06-29 2008-06-25 Promotor

Country Status (15)

Country Link
US (2) US9080183B2 (pt)
EP (1) EP2164972B1 (pt)
JP (1) JP5108942B2 (pt)
KR (1) KR101183764B1 (pt)
CN (1) CN101688222B (pt)
AT (1) ATE535607T1 (pt)
AU (1) AU2008271658B8 (pt)
BR (1) BRPI0813003A2 (pt)
CA (1) CA2690475C (pt)
ES (1) ES2377765T3 (pt)
IL (1) IL201818A0 (pt)
MX (1) MX2009013120A (pt)
RU (1) RU2491344C2 (pt)
TW (1) TWI352737B (pt)
WO (1) WO2009003622A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130045471A1 (en) * 2011-02-25 2013-02-21 Bio-Rad Laboratories, Inc. Training system for investigations of bioengineered proteins
CA2857298A1 (en) 2011-11-30 2013-06-06 Abbvie Biotherapeutics Inc. Vectors and host cells comprising a modified sv40 promoter for protein expression
SG10201805622QA (en) 2011-12-22 2018-08-30 Hoffmann La Roche Expression Vector Organization, Novel Production Cell Generation Methods And Their Use For The Recombinant Production Of Polypeptides
MX355624B (es) * 2011-12-22 2018-04-25 Hoffmann La Roche Combinaciones de elementos de vector de expresion, metodos novedosos de generacion de celulas de produccion y su uso para la produccion recombinante de polipeptidos.
EP3151866B1 (en) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimeric capsids
SG11201703148TA (en) 2014-11-05 2017-05-30 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
CN114717264A (zh) 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
CN107207556B (zh) 2014-11-14 2020-12-08 沃雅戈治疗公司 调节性多核苷酸
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
EP3408397B1 (en) 2016-01-27 2020-07-15 Just-Evotec Biologics, Inc. Hybrid promoter and uses thereof
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
KR102652994B1 (ko) 2016-05-18 2024-04-01 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
IL297576B2 (en) 2016-05-18 2024-02-01 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
EP3506817A4 (en) 2016-08-30 2020-07-22 The Regents of The University of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
CN111108198A (zh) 2017-05-05 2020-05-05 沃雅戈治疗公司 治疗亨廷顿病的组合物和方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
AU2018302016A1 (en) 2017-07-17 2020-02-06 The Regents Of The University Of California Trajectory array guide system
EP3662060A2 (en) 2017-08-03 2020-06-10 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
WO2019067840A1 (en) 2017-09-29 2019-04-04 Voyager Therapeutics, Inc. RESTRICTING CENTRAL AND PERIPHERAL NEUROLOGICAL PHENOTYPE FROM FRIEDREICH ATAXIA BY INTRAVENOUS ADMINISTRATION
EP4454654A3 (en) 2017-10-16 2025-02-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
CA3077426A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
CA3099306A1 (en) 2018-05-15 2019-11-21 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
US12281321B2 (en) 2018-09-28 2025-04-22 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4411499A (en) * 1998-06-05 1999-12-20 Human Genome Sciences, Inc. Connective tissue growth factor-4
JP5623685B2 (ja) * 2003-06-10 2014-11-12 エヌエスゲーネ・アクティーゼルスカブ ニューブラスチンの改良された分泌
JP2006050956A (ja) 2004-08-11 2006-02-23 Japan Science & Technology Agency プルキンエ細胞における遺伝子の発現のための発現ベクター
US20090041783A1 (en) * 2005-04-28 2009-02-12 Mochida Pharmaceutical Co., Ltd. Anti-platelet membrane glycoprotein vi monoclonal antibody

Also Published As

Publication number Publication date
RU2010102812A (ru) 2011-08-10
EP2164972A1 (en) 2010-03-24
CA2690475A1 (en) 2009-01-08
WO2009003622A8 (en) 2009-11-05
IL201818A0 (en) 2011-08-01
JP2010531647A (ja) 2010-09-30
US9926567B2 (en) 2018-03-27
MX2009013120A (es) 2010-01-15
KR20100024438A (ko) 2010-03-05
AU2008271658B8 (en) 2013-07-04
CA2690475C (en) 2014-07-29
US20160083735A1 (en) 2016-03-24
TWI352737B (en) 2011-11-21
CN101688222A (zh) 2010-03-31
KR101183764B1 (ko) 2012-09-17
ES2377765T3 (es) 2012-03-30
AU2008271658B2 (en) 2013-06-06
EP2164972B1 (en) 2011-11-30
AU2008271658A8 (en) 2013-07-04
JP5108942B2 (ja) 2012-12-26
TW200914612A (en) 2009-04-01
WO2009003622A1 (en) 2009-01-08
US20100159489A1 (en) 2010-06-24
ATE535607T1 (de) 2011-12-15
RU2491344C2 (ru) 2013-08-27
CN101688222B (zh) 2013-03-06
AU2008271658A1 (en) 2009-01-08
US9080183B2 (en) 2015-07-14

Similar Documents

Publication Publication Date Title
BRPI0813003A2 (pt) Promotor
ES2691539T3 (es) Luciferasas de Oplophorus sintéticas con mayor emisión de luz
NI200700191A (es) Construcciones de ácido nucleico
IN2012DN05169A (pt)
ES2575906T3 (es) Composiciones y métodos de producir metionina
CR11193A (es) Polipeptidos, dominios variables de anticuerpos y antagonistas
CR11504A (es) Deteccion mejorada de la expresion de mage-a
WO2012049179A3 (en) Polypeptides with kinase activity
ES2676499T3 (es) Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones
MX2015004060A (es) 3-epimerasa.
BR112014019901A2 (pt) proteínas de fator viii recombinante
NZ600205A (en) Selective exosite inhibition of papp-a activity against igfbp-4
PH12014501602B1 (en) Chimeric factor viii polypeptides and uses thereof
WO2010129895A3 (en) Cd133 epitopes
NZ592979A (en) Bovine viral diarrhea virus with a modified erns protein
GB201009493D0 (en) Modified recombinant factor viii and von willebrand factor and methods of use
EA201000327A1 (ru) Белок
EA202190240A1 (ru) Варианты рекомбинантного белка
NZ774126A (en) Spd-1 variant - fc fusion proteins
UA108778C2 (xx) Протираковий злитий протеїн
MX2021006970A (es) Analogos de insulina que tienen una afinidad de union disminuida al receptor de insulina.
MX2012000133A (es) Quimera de adn polimerasa del fago phi29.
UA104933C2 (uk) ЗЛИТИЙ ПОЛІПЕПТИД ПРОТИ ПУХЛИНИ, ІНДУКОВАНОЇ ВІРУСОМ EB, І МУТАНТ КОЛІЦИНУ Ia
MX381723B (es) Metodos novedosos para conjugacion de polipeptido mediada por enzimas usando sortasa.
WO2018069947A8 (en) Nucleotide sequence expressing an exosome-anchoring protein for use as vaccine

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time